Trump Administration Delays Medicare GLP-1 Pilot, Launches Bridge Program Instead

Trump Administration Delays Medicare GLP-1 Pilot Program

The Trump administration has indefinitely delayed a Medicare pilot program for weight-loss drugs. Health insurance companies voiced serious concerns about participating. Federal officials announced the decision on Tuesday. The administration will now cover the drugs through a separate bridge program.

The delayed program was known as BALANCE. It stood for Better Approaches to Lifestyle and Nutrition for Comprehensive Health. CMS announced BALANCE at the end of 2025. The program aimed to bypass Medicare’s existing prohibition on covering weight-loss treatments.

Medicare currently does not cover weight-loss drugs under standard rules. The BALANCE program would have waived that restriction. It would have tested whether covering the medications saved money. It also aimed to determine whether coverage improved health outcomes at no additional cost.

Insurer Resistance Derailed the Original Plan

The BALANCE program required insurers to voluntarily participate. Insurers had until April 20 to commit to the program. Major companies declined to join before that deadline. Their reluctance forced the administration to change course.

CVS Health, which owns Aetna, chose not to opt into BALANCE. UnitedHealth raised its own objections publicly. A company official on UnitedHealth’s earnings call on April 21 cited “notable challenges and outstanding questions.” Those concerns proved decisive in derailing the pilot.

Insurers faced a likely financial strain from participation. The drugmakers agreed to sell treatments for $245 per month. However, Medicare promised beneficiaries a $50 monthly copay. The gap between those figures created a burden insurers refused to absorb.

The Bridge Program Fills the Gap for Seniors

Medicare will not leave seniors without access to these popular medications. CMS confirmed a bridge program to fill the void. The bridge program runs from July 1, 2026, through December 31, 2027. It gives enrollees continued access to GLP-1 weight-loss drugs.

The bridge program operates outside the traditional Medicare Part D benefit framework. CMS described the arrangement as covering medications “outside of the Medicare Part D benefit coverage and payment flow.” This distinction matters for how costs flow through the system. It allows the administration to act without changing existing law.

Medicare enrollees will still pay a $50 monthly copay under the bridge program. Prices come from Trump’s most favored nation agreements with drugmakers. Eli Lilly and Novo Nordisk negotiated those agreements directly with the administration. Both companies confirmed the $50 copay figure for beneficiaries.

Trump’s Earlier Drug Deals Shaped This Policy

President Trump touted deals with Eli Lilly and Novo Nordisk last year. Those deals promised lower prices on GLP-1 drugs. In return, drugmakers gained access to a new pool of patients. The original BALANCE program was the vehicle for delivering that access.

The administration struck the deal to expand access in both Medicare and Medicaid. Eli Lilly sells the popular GLP-1 injectable weight-loss drug Zepbound. Novo Nordisk sells Wegovy, another widely used GLP-1 medication. Both drugs gained enormous popularity among patients seeking obesity treatment.

CMS Administrator Mehmet Oz had championed the BALANCE program publicly. He stated that BALANCE would broaden access and lower prices for obesity GLP-1 medications. He also promised the program would not pass additional costs to taxpayers. Insurer reluctance forced the administration to pursue an alternative path.

Medicaid Portion of BALANCE Continues

Not all parts of the BALANCE program collapsed. CMS confirmed that the Medicaid portion will continue. States may submit applications through July 31, 2026. This keeps one element of the original vision alive.

Medicaid operates differently from Medicare in key ways. The federal government and states jointly fund Medicaid. States directly manage their own Medicaid programs under federal guidance. That structure makes voluntary state participation more workable than mandatory insurer involvement.

State-level participation gives Medicaid enrollees a path to affordable GLP-1 drugs. The federal government continues to encourage states to apply. This divergence between the Medicare and Medicaid tracks reflects the complexity of the policy. Each program faces different legal and financial constraints.

What the Bridge Program Means for Patients

For Medicare enrollees, the bridge program offers near-term relief. Seniors can access GLP-1 medications starting July 1, 2026. The $50 monthly copay remains the same as originally proposed. Access continues through the end of 2027 under the current plan.

Eli Lilly applauded CMS’s decision to launch the bridge program. A company spokesperson said Lilly advocates for broader access to its medications. The company expressed support amid ongoing insurer uncertainty. Novo Nordisk also participates in the pricing agreements that make the bridge program possible.

The arrangement runs only through the end of 2027. Policymakers will need to find a permanent legislative solution to Medicare’s weight-loss drug prohibition. The bridge program buys time but does not resolve the underlying legal restriction. Congress has not yet moved to lift Medicare’s ban on weight-loss drug coverage.

A Policy Setback With a Temporary Fix

The delay marks a significant setback for the Trump administration’s health agenda. Trump personally promoted the drugmaker deals as a win for seniors. The BALANCE program was central to delivering on that promise. Insurer resistance undermined that plan before it fully launched.

The bridge program shows the administration’s determination to preserve some version of the policy. It keeps the $50 copay commitment intact for Medicare beneficiaries. It also maintains the pricing structure negotiated with Eli Lilly and Novo Nordisk. However, the long-term future of GLP-1 coverage in Medicare remains uncertain.

The administration now faces pressure to secure a durable solution. The bridge program expires at the end of 2027. Without legislative action, Medicare’s prohibition on weight-loss drug coverage will reassert itself. The coming months will test whether Washington can find consensus on a permanent fix.